-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Pragmatic Action Seizes the Early Spring—Now Is the Time to Forge Ahead: Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Holds Its 2026 Policy and Target Launch Conference
Category:
TIME：2026-02-12
On February 10, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, held its 2026 Policy and Target Launch Conference. Mid- and senior-level managers from the company gathered to discuss major development strategies and systematically map out a new blueprint for high-quality development in 2026 and during the 15th Five-Year Plan period. The conference was chaired by Zhang Zanyuan, General Manager of Guangxiang Pharmaceutical.
At the meeting, Zhang Zanyuan began by providing an overview of the company’s work in formulating its 2026 policy objectives. He emphasized that these objectives are closely aligned with the Group’s strategic decisions and the “15th Five-Year” strategic plan, while also taking into account the actual development needs of Guangxiang Pharmaceutical. Following multiple rounds of deliberation and thorough validation, a comprehensive annual target system has been established, covering such key dimensions as quality, safety, innovation, and performance, and characterized by both ambition and forward-looking vision.
Let us act with pragmatism and strive to seize the early spring; now is the perfect time to forge ahead. All attendees unanimously pledged to anchor ourselves to the new goals, summoning the vigorous drive to “leave footprints on every stone we tread and marks on every patch of iron we grip” and the tenacious perseverance to “let drops of water wear through even the hardest rock, achieving success only through sustained effort.” We will spare no effort in fully implementing all policies and objectives, ensuring that the key tasks for 2026 are comprehensively put into practice and deliver tangible results, thereby elevating Guangxiang Pharmaceutical’s development to a new height. In doing so, we will present the Group with an outstanding performance that meets and exceeds expectations, and contribute decisively to a strong start and solid foundation for the 15th Five-Year Plan.
During the policy and objective release session, 20 heads from various workshops and departments at Guangxiang Pharmaceutical took to the stage one by one to report on their progress toward the annual targets, making firm commitments, outlining clear pathways, and setting specific action plans. Company leaders listened attentively to each presentation and provided focused feedback and guidance, offering targeted suggestions for enhancement and improvement.
Zhu Shujie, Chairman of Guangxiang Pharmaceutical, delivered a concluding address. He noted that in 2025, all employees of Guangxiang rose to the challenge posed by profound adjustments in both the domestic and international pharmaceutical markets, rigorously implemented the Group’s work plans, and, driven by the courage to “press forward all the more in the face of adversity” and a sense of responsibility that compels them to remain constantly vigilant, worked diligently and tackled tough problems head-on—achievements that were by no means easy to attain. He extended his most sincere gratitude and highest respect to every employee who has devoted their sweat and efforts to the development of Guangxiang Pharmaceutical.
With regard to comprehensively delivering on the 2026 business objectives, Zhu Shujie emphasized that 2026 marks the inaugural year of the company’s 15th Five-Year Plan—a pivotal year characterized by both opportunities and challenges, and one that is critical for breaking through bottlenecks and achieving leapfrog development. He urged management at all levels and all employees to fully, accurately, and comprehensively implement the new development philosophy, foster a new development paradigm, further align their thinking and actions with the strategic directives of the Group’s Board of Directors, and steadfastly anchor themselves to the goal of high-quality development. Specifically, he called for: first, taking strengthened management as the overarching priority, rigorously assigning responsibilities and boosting execution effectiveness to ensure that all of the Group’s management requirements are effectively implemented and take root at Guangxiang Pharmaceutical; second, regarding quality and safety as the lifeline, building a solid foundation for steady growth, and resolutely safeguarding the areas of responsibility entrusted to the company by the Group; third, using cost reduction and efficiency enhancement as the breakthrough point to strengthen competitive edge and contribute Guangxiang Pharmaceutical’s strength to the overall improvement of the Group’s performance; fourth, positioning innovation as the core engine to unleash new momentum for high-quality development and better integrate into the Group’s science-and-technology innovation system; and fifth, leveraging project applications as a key support to expand new avenues for development and demonstrate greater impact within the Group’s strategic blueprint.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
